RFA-DK-22-501: Limited Competition for the Continuation of HiLo: Pragmatic Trial of Higher versus Lower Serum Phosphate Targets in Patients Undergoing Hemodialysis Clinical Centers (UH3- Clinical Trial Required)
Closed
This grant is closed. Who won this program's grants before is below, and similar open grants are at the end of the page. It is in our archive of National Institutes of Health notices from 2022.
National Institutes of Health offered grants of up to $1.0 million to small businesses. Applications closed on October 19, 2022.
From the official notice on Grants.gov, last changed June 9, 2022. Checked November 7, 2026.
- Award ceiling$1.0 million
- Cost sharingNot required
- Funding typeCooperative Agreement
About this NIH notice
- Activity codeUH3
- Clinical trialsRequired
- Funded byNIDDK
- Median yearly award$450,000
- Typical project length6.5 years
- UH3, Exploratory/Developmental Cooperative Agreement Phase II. The second phase of a phased cooperative agreement, usually following a UG3 or UH2 phase. Other open UH3 notices.
Projects funded under RFA-DK-22-501 were run by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK, 1 project). Contact the program officer at the institute that fits your project before you apply; the notice lists them.
Application due dates, page limits and budget limits are set in the notice. Read RFA-DK-22-501 in the NIH Guide.
Key dates
| Posted | June 8, 2022 |
|---|---|
| Deadline | October 19, 2022 |
| Archived by Grants.gov | November 24, 2022 |
Who can apply
This opportunity was open to small businesses.
- Small businesses
Other Eligible Applicants include the following: Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are allowed. See Full Announcement for additional information on eligibility
Is this a realistic fit?
- Projects NIH funded under this notice had a median yearly award of $450,000; it allows up to $1.0 million per award.
- Most of the program's money (70% over five years) went to colleges and universities.
- No cost sharing or match is required.
What the grant funds
This Funding Opportunity Announcement (FOA) invites a renewal application from UH3 DK118748 supported by RFA-RM-16-019. This FOA will support the continuation and completion of HiLo: A pragmatic trial of higher vs lower serum phosphate targets in patients undergoing hemodialysis. The awardee will continue to enroll and follow hemodialysis patients in the HiLo trial to its completion.
Funded under RFA-DK-22-501 so far
NIH funded 1 project under RFA-DK-22-501 in fiscal 2024, at 1 institution. The median yearly award was $450,000.
| Project | Institution | Fiscal year | Award |
|---|---|---|---|
| HiLo Competitive Renewal | Duke University | 2024 | $450,000 |
Who has won Diabetes, Digestive, and Kidney Diseases Extramural Research grants before
From fiscal 2021 to 2025, Diabetes, Digestive, and Kidney Diseases Extramural Research (93.847) awarded $9.6 billion across 7,877 grant awards, an average of $1.2 million per award.
| Recipient | State | Awards | Amount |
|---|---|---|---|
| Regents of the University of Michigan | Michigan | 273 | $345 million |
| The Trustees of the University of Pennsylvania | Pennsylvania | 187 | $272 million |
| University of Pittsburgh - of the Commonwealth System of Higher Education | Pennsylvania | 209 | $238 million |
| The Washington University | Missouri | 187 | $227 million |
| The Regents of the University of California, San Francisco | California | 176 | $208 million |
Applying now
This notice no longer takes applications. Agencies often post the same opportunity again under a new number, so check the program's notices on Grants.gov and the similar open grants below.
The notice on Grants.gov keeps its full text and attachments, which is useful for planning a resubmission.
Questions people ask
Is RFA-DK-22-501 still open?
No. It closed on October 19, 2022.
Who can apply for Limited Competition for the Continuation of HiLo: Pragmatic Trial of Higher versus Lower Serum Phosphate Targets in Patients Undergoing Hemodialysis Clinical Centers (UH3- Clinical Trial Required)?
National Institutes of Health accepted applications from small businesses. The notice adds further conditions, so read its eligibility section.
What is the deadline for Limited Competition for the Continuation of HiLo: Pragmatic Trial of Higher versus Lower Serum Phosphate Targets in Patients Undergoing Hemodialysis Clinical Centers (UH3- Clinical Trial Required)?
Closed October 19, 2022. Applications are no longer accepted; the program's newer notices are on this page when there are any.
How much funding is available?
Awards of up to $1.0 million each.
Who has been funded under RFA-DK-22-501?
NIH RePORTER lists 1 project funded under RFA-DK-22-501 in fiscal 2024, at 1 institution.
Who has won Diabetes, Digestive, and Kidney Diseases Extramural Research grants before?
The largest recipients over five fiscal years were Regents of the University of Michigan, The Trustees of the University of Pennsylvania, University of Pittsburgh - of the Commonwealth System of Higher Education. The program made 7,877 awards worth $9.6 billion in that time.
Similar open grants
- Clinical Trials and Ancillary Studies Conducted within NIH-Funded Clinical Trial Research Networks (UG3/UH3 - Clinical Trial Required)
- NIH StrokeNet Clinical Trials and Biomarker Studies for Stroke Treatment, Recovery, and Prevention (UG3/UH3 Clinical Trial Optional)
- Seamless Early-Stage Clinical Drug Development (Phase 1 to 2a) for Novel therapeutic Agents for the Spectrum of Alzheimer's Disease (AD) and AD-related Dementias (ADRD) (UG3/UH3 Clinical Trial Required)
- Cellular Senescence Network (SenNet): SenNet Technology Projects (SenTecs) (UG3/UH3 Clinical Trial Not Allowed)
- Multi-Site Investigator-Initiated Clinical Trials (Collaborative UG3/UH3 Clinical Trial Required)
- NIAMS Clinical Trial Implementation Cooperative Agreement (UG3/UH3 Clinical Trial Required)